Voclosporin | A calcineurin inhibitor for the treatment of lupus nephritis (LN) in patients diagnosed with systemic lupus erythematosus (SLE). |
Cetuximab | An endothelial growth factor receptor binding fragment used to treat colorectal cancer as well as squamous cell carcinoma of the head and neck. |
Denileukin diftitox | A recombinant cytotoxic protein based on a combination of diphtheria toxin fragments and interleukin-2 used to treat cutaneous T-cell lymphoma by targeting the interleukin-2 receptor. |
Leuprolide | A peptide-based GnRH receptor superagonist used for the palliative treatment of prostate cancer, uterine leiomyomata, endometriosis, and central precocious puberty. |
Peginterferon alfa-2a | A modified form of recombinant human interferon used to stimulate the innate antiviral response in the treatment of hepatitis B and C viruses. |
Interferon alfa-n1 | A purified form of human interferon used to stimulate the innate antiviral response in the treatment of genital warts due to human papilloma virus. |
Goserelin | A synthetic analog of luteinizing hormone-releasing hormone used to treat breast cancer and prostate cancer by reducing secretion of gonadotropins from the pituitary. |
Pegfilgrastim | A recombinant human granulocyte colony stimulating factor used to stimulate the production of neutrophils and prevent febrile neutropenia or infections after myelosuppressive chemotherapy. |
Sargramostim | A modified form of recombinant human granulocyte-macrophage colony stimulating factor used to increase immune cell production after myelosuppressive therapy or bone marrow transplant. |
Peginterferon alfa-2b | A purified form of human interferon used to stimulate the innate antiviral response in the treatment of hepatitis B and C, genital warts, and some cancers. |
Asparaginase Escherichia coli | An asparaginase enzyme from E. coli used as part of treatment regimens for acute lymphoblastic leukemias. |
Anakinra | A recombinant form of human interleukin-1 receptor antagonist used in the treatment of rheumatoid arthritis and neonatal-onset multisystem inflammatory disease. |
Interferon alfa-2a | A form of recombinant human interferon used to stimulate the innate antiviral response in the treatment of hepatitis B and C viruses. |
Oprelvekin | A form of recombinant interleukin-11 used to stimulate production of megakaryocytes and platelets in patients with or at risk of thrombocytopenia after chemotherapy. |
Aldesleukin | A recombinant analog of interleukin-2 used to induce an adaptive immune response in the treatment of renal cell carcinoma. |
Adalimumab | A monoclonal anti-tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis. |
Gemtuzumab ozogamicin | A monoclonal anti-CD33 antibody used to treat CD33-positive acute myeloid leukemia. |
Pegaspargase | A modified form of L-asparagine amidohydrolase used to treat acute lymphoblastic leukemia, which is dependent on an external source of asparagine. |
Interferon beta-1a | A form of recombinant human interferon used to slow disease progression and reduce the frequency of clinical symptoms in patients who have relapsing multiple sclerosis. |
Infliximab | A monoclonal anti tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis. |
Interferon beta-1b | A form of recombinant human interferon used to slow the progression of relapsing multiple sclerosis and to reduce the frequency of clinical symptoms. |
Interferon alfacon-1 | A recombinant interferon similar the interferon alfa subtype which is used to treat hepatitis C infections. |
Trastuzumab | A monoclonal anti-human epidermal growth factor receptor 2 protein antibody used to treat HER2-positive breast, gastroesophageal, and gastric cancers. |
Basiliximab | A monoclonal anti-C25 antibody (interleukin-2 receptor alpha subunit) used as immunosuppressive therapy in kidney transplant patients. |
Muromonab | A monoclonal anti-CD3 antibody used as immunosuppressive therapy in kidney, heart, and liver transplant patients. |
Alemtuzumab | A monoclonal anti-CD52 antibody used in the treatment of B-cell chronic lymphocytic leukemia and relapsing forms of multiple sclerosis. |
Alefacept | A recombinant fusion protein that binds CD2 and is used treat moderate to severe plaque psoriasis. |
Efalizumab | A monoclonal anti-CD11a antibody used to treat moderate to severe plaque psoriasis. |
Antithymocyte immunoglobulin (rabbit) | A purified form of rabbit anti-thymocyte antibodies used for immunosuppression in patients receiving kidney transplants. |
Filgrastim | A form of recombinant human granulocyte colony stimulating factor used to induce the production of granulocytes and lower infection risk after myelosuppressive therapy. |
Interferon alfa-2b | A form of recombinant human interferon used to treat hepatitis B and C infection, genital warts, hairy cell leukemia, follicular lymphoma, malignant melanoma, and AIDs-related Kaposi's sarcoma. |
Abarelix | For palliative treatment of advanced prostate cancer. |
Natalizumab | A monoclonal anti-integrin antibody which binds to the alpha 4 subunit of integrins to prevent migration of immune cells, and is used to treat Crohn's disease or multiple sclerosis. |
Daclizumab | A monoclonal anti-CD25 antibody that blocks the interleukin-2 receptor which is used to treat relapsing forms of multiple sclerosis. |
Bevacizumab | A monoclonal anti-vascular endothelial growth factor antibody used in combination with antineoplastic agents for the treatment of many types of cancer. |
Masoprocol | Used for the treatment of actinic keratoses (precancerous skin growths that can become malignant if left untreated). |
Bortezomib | A proteasome inhibitor used to treat multiple myeloma in patients who have not been successfully treated with at least two previous therapies. |
Pipobroman | For the treatment of polycythaemia vera and refractory chronic myeloid leukaemia. |
Cladribine | A purine antimetabolite used for the management of relapsing forms of Multiple Sclerosis (MS), used in patients who have not responded to or who were unable to tolerate alternative MS drugs. |
Diethylstilbestrol | Used in the treatment of prostate cancer. Previously used in the prevention of miscarriage or premature delivery in pregnant women prone to miscarriage or premature delivery. |
Anagrelide | A platelet-reducing agent used to treat thrombocythemia, and its related complications, secondary to myeloproliferative neoplasms. |
Carmustine | An alkylating agent used in the treatment of various malignancies, including brain tumours and multiple myeloma, among others. |
Amsacrine | A cytotoxic agent used to induce remission in acute adult leukemia that is not adequately responsive to other agents. |
Bleomycin | A chemotherapy agent used to treat various malignancies, including head and neck malignancy, lymphoma, and testicular tumors, among others. |
Chlorambucil | A chemotherapy agent used in the management of chronic lymphocytic leukemia and malignant lymphomas. |
Raltitrexed | A folate analog thymidylate synthase inhibitor used in the treatment of advanced colorectal cancer. |
Mitomycin | An antimetabolite used as an adjunct to ab externo (outside approach) eye surgeries for the treatment of glaucoma and used as a chemotherapeutic agent for various malignancies. |
Bexarotene | A retinoid drug used for cutaneous manifestations of T-cell lymphoma in patients who have not responded well to previous systemic therapy. |
Vindesine | A vinca alkaloid derived from vinblastine used for various types of malignancies, but mainly acute lymphocytic leukemia (ALL). |
Gefitinib | A tyrosine kinase inhibitor used as first-line therapy to treat non-small cell lung carcinoma (NSCLC) that meets certain genetic mutation criteria. |
Tioguanine | A purine analogue antineoplastic agent used for the induction of remission, and for remission consolidation in patients with acute nonlymphocytic anemias. |
Aminoglutethimide | An adrenocortical steroid synthesis inhibitor used in the treatment of Cushing's syndrome. |
Vinorelbine | A vinca alkaloid used in the treatment of metastatic non-small cell lung carcinoma (NSLC) and in conjunction with other drugs in locally advanced NSCLC. |
Valrubicin | An anthracycline used intravesically in the treatment of BCG-resistant bladder carcinoma. |
Sorafenib | A kinase inhibitor used in the treatment of unresectable liver carcinoma and advanced renal carcinoma. |
Streptozocin | A nitrosourea antineoplastic agent used in the treatment of metastatic pancreatic islet cell carcinoma. |
Gemcitabine | A nucleoside metabolic inhibitor used as adjunct therapy in the treatment of certain types of ovarian cancer, non-small cell lung carcinoma, metastatic breast cancer, and as a single agent for pancreatic cancer. |
Teniposide | A cytotoxic drug used as an adjunct for chemotherapy induction in the treatment of refractory childhood acute lymphoblastic leukemia. |
Epirubicin | An anthracycline topoisomerase II inhibitor used as an adjuvant to treating axillary node metastases in patients who have undergone surgical resection of primary breast cancer. |
Lenalidomide | A thalidomide derivative used to treat multiple myeloma and anemia in low to intermediate risk myelodysplastic syndrome. |
Altretamine | An antineoplastic agent used in palliative treatment of persistent or recurrent ovarian cancer. |
Flutamide | An antiandrogen used for locally confined stage B2-C and D-2 metastatic prostate carcinoma. |
Cisplatin | A platinum based chemotherapy agent used to treat various sarcomas, carcinomas, lymphomas, and germ cell tumors. |
Alitretinoin | A vitamin A derivative used to treat Kaposi's sarcoma and used off label to treat chronic hand eczema and psoriasis. |
Oxaliplatin | A platinum based chemotherapy agent used to treat carcinoma of the colon or rectum or stage III colon cancer. |
Erlotinib | An EGFR tyrosine kinase inhibitor used to treat certain small cell lung cancers or advanced metastatic pancreatic cancers. |
Cyclophosphamide | A nitrogen mustard used to treat lymphomas, myelomas, leukemia, mycosis fungoides, neuroblastoma, ovarian adenocarcinoma, retinoblastoma, and breast carcinoma. |
Toremifene | A first generation nonsteroidal selective estrogen receptor modulator used to treat certain breast cancers. |
Vincristine | A vinca alkaloid used to treat acute leukemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis. |
Fluorouracil | A pyrimidine analog used to treat basal cell carcinomas, and as an injection in palliative cancer treatment. |
Pentostatin | An adenosine deaminase inhibitor used to treat hairy cell leukemia. |
Methotrexate | An antineoplastic agent used the treatment of a wide variety of cancers as well as severe psoriasis, severe rheumatoid arthritis, and juvenile rheumatoid arthritis. |
Vinblastine | A vinca alkaloid used to treat breast cancer, testicular cancer, neuroblastoma, Hodgkin's and non-Hodgkins lymphoma, mycosis fungoides, histiocytosis, and Kaposi's sarcoma. |
Imatinib | A tyrosine kinase inhibitor used to treat a number of leukemias, myelodysplastic/myeloproliferative disease, systemic mastocytosis, hypereosinophilic syndrome, dermatofibrosarcoma protuberans, and gastrointestinal stromal tumors. |
Clofarabine | A purine nucleoside used to treat relapsed or refractory acute lymphoblastic leukemia in patients 1 to 21 years old. |
Pemetrexed | A folate analog used to treat mesothelioma and non-small cell lung cancer. |
Mitotane | An adrenal cortex inhibitor used to treat adrenocortical tumors and Cushing's syndrome. |
Nilutamide | An antineoplastic hormone used to treat prostate cancer. |
Tamoxifen | A selective estrogen receptor modulator used to treat estrogen receptor positive breast cancer, reduce the risk of invasive breast cancer following surgery, or reduce the risk of breast cancer in high risk women. |
Daunorubicin | An anthracycline aminoglycoside used to induce remission of nonlymphocytic leukemia and acute lymphocytic leukemia. |
Porfimer sodium | A hematoporphyrin derivative used to treat esophageal cancer, endobronchial cancer, and high grade dysplasia in Barrett's Esophagus. |
Irinotecan | An antineoplastic enzyme inhibitor used to treat metastatic carcinoma of the colon or rectum. |
Etoposide | A podophyllotoxin derivative used to treat testicular and small cell lung tumors. |
Dacarbazine | An antineoplastic agent used to treat malignant melanoma and Hodgkin's disease. |
Temozolomide | An alkylating agent used to treat glioblastoma multiforme and refractory anaplastic astrocytoma. |
Aminolevulinic acid | A porphyrin precursor used to treat actinic keratosis of the face, scalp, and upper extremities, as well as to visualize a glioma. |
Tacrolimus | A calcineurin inhibitor used to prevent organ transplant rejection and to treat moderate to severe atopic dermatitis. |
Sirolimus | An immunosuppressant used to prevent organ transplant rejections and to treat lymphangioleiomyomatosis. |
Mechlorethamine | An antineoplastic agent used to treat Hodgkin's disease, lymphosarcoma, and chronic myelocytic or lymphocytic leukemia. |
Azacitidine | A pyrimidine nucleoside analogue used to treat certain subtypes of myelodysplastic syndrome. |
Fulvestrant | An estrogen receptor antagonist used to treat HR+ breast cancer that may also be HER2-. |
Carboplatin | A alkylating agent used to treat advanced ovarian cancer. |
Dactinomycin | An actinomycin used to treat a wide variety of cancers. |
Cytarabine | A pyrimidine nucleoside analogue used to treat acute non-lymphocytic leukemia, lymphocytic leukemia, and the blast phase of chronic myelocytic leukemia. |
Exemestane | An aromatase inhibitor used to treat breast cancer in postmenopausal women after treatment with tamoxifen. |
Methyl aminolevulinate | A porphyrin precursor used to treat non-hyperkeratotic, non-pigmented actinic keratosis of the face and scalp. |
Azathioprine | An immunosuppressant used to prevent renal transplant rejection, treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis. |
Doxorubicin | A medication used to treat various cancers and Kaposi's Sarcoma. |
Hydroxyurea | An antimetabolite used to treat sickle cell anemia crisis. |
Letrozole | An aromatase inhibitor used to treat breast cancer in postmenopausal women. |
Busulfan | An alkylating agent used to treat chronic myelogenous leukemia. |
Mycophenolic acid | An immunosuppressant used to prevent organ transplant rejections. |
Topotecan | An antineoplastic agent used to treat ovarian cancer, small cell lung cancer, or cervical cancer. |
Mercaptopurine | An antineoplastic agent used to treat acute lymphocytic leukemia. |
Thalidomide | A medication used to treat newly diagnosed multiple myeloma and erythema nodosum leprosum. |
Melphalan | An alkylating antineoplastic agent used to treat multiple myeloma and ovarian carcinoma. |
Fludarabine | A purine analog antimetabolite that inhibits DNA synthesis. |
Leflunomide | A pyrimidine synthesis inhibitor indicated to treat rheumatoid arthritis. |
Capecitabine | A nucleoside metabolic inhibitor indicated to treat colon, colorectal and breast cancer. |
Bicalutamide | An androgen receptor inhibitor used to treat Stage D2 metastatic carcinoma of the prostate. |
Procarbazine | An antineoplastic agent indicated for the treatment of stage III and stage IV Hodgkin's disease in combination with other chemotherapeutic agents. |
Arsenic trioxide | A chemotherapeutic agent used in the treatment of refractory or relapsed acute promyelocytic leukemia in patients with prior retinoid and anthracycline chemotherapy. |
Idarubicin | An anthracycline antineoplastic agent used to treat acute myeloid leukemia (AML) in adults. |
Ifosfamide | An alkylating and immunosuppressive agent used in chemotherapy for the treatment of cancers, including testicular cancer, ovarian cancer, cervical cancer, osteocarcinoma, bladder cancer, small cell lung cancer, and non-Hodgkin's lymphoma. |
Estramustine | An antineoplastic agent used for the management of metastatic and/or progressive prostate cancer in palliative setting. |
Mitoxantrone | A chemotherapeutic agent used for the treatment of secondary progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis. |
Lomustine | An alkylating agent used as a part of chemotherapeutic regimens for the treatment of primary and metastatic brain tumors as well as refractory or relapsed Hodgkin's disease in addition to surgical and/or radiotherapeutic treatments. |
Anastrozole | A competitive, selective, non-steroidal aromatase inhibitor used as adjuvant therapy for the treatment of hormone receptor-positive breast cancer in postmenopausal women. |
Paclitaxel | A taxoid chemotherapeutic agent used as first-line and subsequent therapy for the treatment of advanced carcinoma of the ovary, and other various cancers including breast and lung cancer. |
Docetaxel | A taxoid antineoplastic agent used in the treatment of various cancers, such as locally advanced or metastatic breast cancer, metastatic prostate cancer, gastric adenocarcinoma, and head and neck cancer. |
Dasatinib | A tyrosine kinase inhibitor used for the treatment of lymphoblastic or chronic myeloid leukemia with resistance or intolerance to prior therapy. |
Eculizumab | A recombinant humanized monoclonal antibody used to reduce the risk of hemolysis in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). |
Lapatinib | An antineoplastic agent and tyrosine kinase inhibitor used for the treatment of advanced or metastatic HER-negative breast cancer in patients who received prior chemotherapeutic treatments. |
Decitabine | A chemotherapeutic pyrimidine nucleoside analogue used for the treatment of myelodysplastic syndromes (MDS) by inducing DNA hypomethylation and corresponding alterations in gene expression. |
Sunitinib | A receptor tyrosine kinase inhibitor and chemotherapeutic agent used for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). |
Panitumumab | A recombinant humanized monoclonal antibody used to treat EGFR-expressing, metastatic colorectal carcinoma that is refractory to fluoropyrimidine-, oxaliplatin-, and irinotecan- containing chemotherapy regimens. |
Nelarabine | A purine nucleoside analog and antineoplastic agent used for the treatment of with acute T-cell lymphoblastic leukemia and T-cell lymphoblastic lymphoma with inadequate clinical response to prior chemotherapeutic treatments. |
Abatacept | A disease-modifying antirheumatic drug (DMARD) used for the management of moderate-to-severe active rheumatoid arthritis and active polyarticular juvenile idiopathic arthritis as monotherapy or in combination with other DMARDs. |
Everolimus | A mammalian target of rapamycin (mTOR) kinase inhibitor used to treat various types of malignancies. |
Vorinostat | A histone deacetylase (HDAC) inhibitor used for the treatment of cutaneous manifestations in patients with progressive, persistent, or recurrent cutaneous T- cell lymphoma (CTCL) following prior systemic therapies. |
Fotemustine | Not Available |
Thiotepa | An alkylating agent used to prevent graft rejection in stem cell transplantation and to treat a variety of malignancies including certain types of adenocarcinoma and superficial bladder carcinomas. |
Ixabepilone | A microtubule inhibitor administered in combination with capecitabine or alone in the treatment of metastatic or locally advanced breast cancer that has shown inadequate response to taxanes and anthracyclines. |
Cediranib | For the treatment of liver cancer, advanced non-small cell lung cancer (NSCLC), advanced colorectal cancer (CRC) and other solid tumors. |
Omacetaxine mepesuccinate | A cephalotaxine used in the treatment of Chronic Myeloid Leukemia (CML) that is intolerant to or resistant to two or more tyrosine kinase inhibitors. |
Nilotinib | A kinase inhibitor used for the chronic phase treatment of Chronic Myeloid Leukemia (CML) that is Philadelphia chromosome positive and for the treatment of CML that is resistant to therapy containing imatinib. |
Sitimagene ceradenovec | Intended for the treatment of brain cancer. |
Pirfenidone | An agent used for the treatment of idiopathic pulmonary fibrosis (IPF). |
Afelimomab | Investigated for use/treatment in sepsis and septicemia. |
Satraplatin | Investigated for use/treatment in lung cancer, prostate cancer, and solid tumors. |
Belinostat | A histone deacetylase (HDAC) inhibitor used for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). |
Trabectedin | An alkylating agent approved for the treatment of unresectable or metastatic soft tissue sarcoma (liposarcoma or leiomyosarcoma). |
Vintafolide | Investigated for use/treatment in solid tumors. |
Glatiramer | An immunomodulator used to reduce the frequency of relapses in Multiple Sclerosis (MS). |
Vandetanib | An antineoplastic kinase inhibitor used to treat symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. |
Albinterferon Alfa-2B | Investigated for use/treatment in hepatitis (viral, C). |
Briakinumab | Investigated for use/treatment in autoimmune diseases, crohn's disease, multiple sclerosis, psoriasis and psoriatic disorders, and rheumatoid arthritis. |
Ramucirumab | An antineoplastic agent and direct VEGFR2 (vascular endothelial growth factor receptor 2) antagonist that blocks the binding of natural VEGF ligands, which are secreted by solid tumors to promote angiogenesis and enhance tumor blood supply. |
Apremilast | A non-steroidal medication used for the treatment of inflammatory conditions such as psoriasis and psoriatic arthritis. |
Ustekinumab | A targeted antibody therapy used to manage inflammatory conditions such as plaque psoriasis, psoriatic arthritis, Crohn's Disease, and ulcerative colitis. |
Trastuzumab emtansine | An antineoplastic agent and antibody-drug conjugate used to treat HER2-overexpressing breast cancer. |
Abiraterone | An antiandrogen used in the treatment of prostate cancer. |
Canakinumab | An interleukin-1β blocker used to treat Periodic Fever Syndromes such as Cryopyrin-Associated Periodic Syndromes (CAPS) and Familial Mediterranean Fever (FMF), and also to treat active Systemic Juvenile Idiopathic Arthritis (SJIA). |
Romidepsin | A histone deacetylase (HDAC) inhibitor used to treat cutaneous and peripheral T-cell lymphoma. |
Ipilimumab | A human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma. |
Pixantrone | An antineoplastic agent use to treat patients with relapsed or refractory aggressive Non-Hodgkin B-cell Lymphomas (NHL). |
Ridaforolimus | Investigated for use/treatment in solid tumors, sarcoma, cancer/tumors (unspecified), endometrial cancer, prostate cancer, and bone metastases. |
Amrubicin | Investigated for use/treatment in lung cancer . |
Lonidamine | Investigated for use/treatment in benign prostatic hyperplasia, prostate disorders, and cancer/tumors (unspecified). |
Tocilizumab | An interleukin-6 (IL-6) receptor antagonist used to treat Cytokine Release Syndrome (CRS), Systemic Juvenile Idiopathic Arthritis (sJIA), Giant Cell Arteritis (GCA), and Rheumatoid Arthritis (RA). |
Temsirolimus | A antineoplastic agent used in the treatment of renal cell carcinoma (RCC) that works by inhibiting mTOR. |
Pertuzumab | An antineoplastic agent used in the treatment of HER2-positive metastatic breast cancer in combination with other antineoplastic agents. |
Rilonacept | An IL-1 inhibitor used to treat cryopyrin-associated periodic syndrome, a rare hereditary inflammatory disorder. |
Pazopanib | An antineoplastic agent used in the treatment of advanced renal cell cancer and advanced soft tissue sarcoma in patients with prior chemotherapy. |
Panobinostat | A non-selective histone deacetylase inhibitor used to treat multiple myeloma in combination with other antineoplastic agents. |
Catumaxomab | For use in the management of malignant ascites tumours via intraperitoneal infusion where standard therapy is not available or feasible [FDA Label]. |
Bosutinib | An antineoplastic agent used for the treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) in adults with inadequate clinical response to other treatments. |
Axitinib | An oral VEGFR and kinase inhibitor used for the treatment of advanced renal cell carcinoma after failure of one prior systemic therapy. |
Ofatumumab | An anti-CD20 antibody used for the treatment of chronic lymphocytic leukemia (CLL) in selected patients with certain treatment histories and responsiveness to anticancer medications. |
Abetimus | Investigated for use/treatment in kidney disease and systemic lupus erythematosus. |
Golimumab | A TNFα inhibitor used in the symptomatic treatment of various active inflammatory disorders, such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis. |
Belatacept | A selective T-cell costimulation blocker used in the prophylaxis of organ rejection in adult patients receiving a kidney transplant. |
Sipuleucel-T | An autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. |
Degarelix | A GnRH receptor antagonist used in the management of advanced prostate cancer. |
Buserelin | A LHRH agonist used for the palliative treatment of hormone-dependent advanced carcinoma of the prostate gland in males and treatment of endometriosis in females. |
Bendamustine | An antineoplastic agent used for the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed following rituximab therapy. |
Cabazitaxel | An antineoplastic agent used for the treatment of hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing treatment regimen. |
Histrelin | A GnRH agonist found in subcutaneous implants used for the treatment of pediatric patients with central precocious puberty and the palliative treatment of advanced prostate cancer. |
Plerixafor | A selective chemokine receptor (CXCR4) antagonist used with filgrastim to mobilize hematopoietic stem cells to the peripheral blood for collection and autologous transplantation in patients with non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM). |
Plicamycin | For the treatment of testicular cancer, as well as hypercalcemia and hypercalciuria associated with a variety of advanced forms of cancer. |
Pralatrexate | An antineoplastic agent used for the treatment of relapsed or refractory peripheral T-cell lymphoma. |
Triptorelin | A GnRH agonist indicated for the palliative treatment of advanced prostate cancer. |
Efaproxiral | Not Available |
Vismodegib | A hedgehog pathway inhibitor used to treat patients with locally advanced or metastatic basal cell carcinoma. |
Crizotinib | A receptor tyrosine kinase inhibitor used to treat metastatic non-small cell lung cancer (NSCLC) where the tumors have been confirmed to be anaplastic lymphoma kinase (ALK), or ROS1-positive. |
Fingolimod | A sphingosine 1-phosphate receptor modulator used to treat patients with the relapsing-remitting form of multiple sclerosis (MS) and studied to manage lung complications of COVID-19. |
Brentuximab vedotin | A CD30-directed antibody-drug conjugate used to treat various types of lymphoma. |
Eribulin | A microtubule inhibitor used to treat metastatic breast cancer and metastatic or unresectable liposarcoma. |
Cabozantinib | A tyrosine kinase inhibitor used to treat advanced renal cell carcinoma, hepatocellular carcinoma, and medullary thyroid cancer. |
Ruxolitinib | A kinase inhibitor used to treat various types of myelofibrosis, polycythemia vera in patients who have not responded to or cannot tolerate hydroxyurea, and to treat graft-versus-host disease in cases that are refractory to steroid treatment. |
Belimumab | A B-lymphocyte stimulator (BLyS)-specific inhibitor that indirectly inhibits B cell survival, and is used to treat patients with autoantibody positive, active systemic lupus erythematosus. |
Teriflunomide | A pyrimidine synthesis inhibitor with anti-inflammatory and immunomodulatory properties used to treat patients with the relapsing-remitting form of multiple sclerosis. |
Vemurafenib | A kinase inhibitor used to treat patients with Erdheim-Chester Disease who have the BRAF V600 mutation, and melanoma in patients who have the BRAF V600E mutation. |
Carfilzomib | A proteasome inhibitor used either alone or in conjunction with a chemotherapy regimen to treat patients with relapsed or refractory multiple myeloma. |
Tofacitinib | A Janus kinase (JAK) inhibitor used to treat rheumatoid and psoriatic arthritis, and ulcerative colitis. It is not recommended to be combined with biologic therapies or potent immunosuppressants like cyclosporine or azathioprine. |
Regorafenib | A kinase inhibitor used to treat patients with metastatic colorectal cancer, unresectable, locally advanced, or metastatic gastrointestinal stromal tumors, and hepatocellular carcinoma. |
Enzalutamide | An androgen receptor inhibitor used to treat castration-resistant prostate cancer. |
Ponatinib | A kinase inhibitor used to treat patients with various types of chronic myeloid leukemia (CML). |
Certolizumab pegol | A tumor necrosis factor (TNF) blocker used to treat a variety of autoimmune and autoinflammatory conditions like Crohn's disease, rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, and plaque psoriasis. |
Formestane | For the treatment of estrogen-receptor positive breast cancer in post-menopausal women. |
Pomalidomide | A thalidomide analogue used in combination with dexamethasone to treat patients with multiple myeloma. |
Trametinib | A kinase inhibitor used to treat patients with specific types of melanoma, non-small cell lung cancer, and thyroid cancer. |
Dabrafenib | A kinase inhibitor used to treat patients with specific types of melanoma, non-small cell lung cancer, and thyroid cancer. |
Afatinib | An antineoplastic agent used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with non-resistant EGFR mutations or resistance to platinum-based chemotherapy. |
Obinutuzumab | An antineoplastic CD20 antibody used to treat untreated chronic lymphocytic leukemia in combination with chlorambucil. |
Carmofur | Carmofur is a derivative of fluorouracil, and is an antineoplastic agent that has been used in the treatment of breast and colorectal cancer. Carmofur has been known to induce leukoencephalopathy. |
Secukinumab | An immunomodulating agent and interleukin antagonist used to manage moderate to severe plaque psoriasis and active psoriatic arthritis or ankylosing spondylitis. |
Vedolizumab | An integrin blocker and anti-inflammatory agent used to manage ulcerative colitis and Crohn's disease in adults with inadequate clinical response to immunomodulators. |
Nivolumab | A PD-1 blocking antibody used to treat melanoma, non small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma. |
Siltuximab | An interleukin antagonist used to treat multicentric Castleman's disease (MCD) in patients who are HIV and HHV-8 negative. |
Pembrolizumab | A PD-1 blocking antibody used to treat various types of cancer, including metastatic melanoma, non small-cell lung cancer, cervical cancer, head and neck cancer, and Hodgkin's lymphoma. |
Blinatumomab | An antineoplastic antibody used to treat Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). |
Ibrutinib | An antineoplastic agent used to treat chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's Macroglobulinemia. |
Idelalisib | An antineoplastic kinase inhibitor used to treat chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). |
Ceritinib | An antineoplastic kinase inhibitor used to treat anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) in patients with inadequate clinical response or intolerance to crizotinib. |
Palbociclib | An endocrine-based chemotherapeutic agent used in combination with other antineoplastic agents to treat HER2-negative and HR-positive advanced or metastatic breast cancer. |
Olaparib | A chemotherapeutic agent used to treat recurrent or advanced ovarian cancer and metastatic breast cancer in patients with specific mutations and prior history of chemotherapy. |
Dinutuximab | An immunotherapeutic agent used in combination with other immunomodulating agents to treat high-risk neuroblastoma in pediatric patients who achieve at least a partial response to prior first-line multiagent, multimodality therapy. |
Lenvatinib | A receptor tyrosine kinase inhibitor used for the treatment of metastatic thyroid cancer, advanced renal cell carcinoma in combination with everolimus, and unresectable hepatocellular carcinoma. |
Nintedanib | A triple angiokinase inhibitor indicated for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and in combination with docetaxel for non-small cell lung cancer. |
Ancestim | A human stem cell factor used in combination with filgrastim during autologous peripheral blood progenitor cell (PBPC) transplantation to increase PBPC mobilization for improved collection. |
Peginterferon beta-1a | An interferon beta used to treat relapsing forms of multiple sclerosis. |
Sonidegib | An antineoplastic agent used for the treatment of locally advanced recurrent basal cell carcinoma (BCC) following surgery and radiation therapy, or in cases where surgery or radiation therapy are not appropriate. |
Tegafur | An antineoplastic agent used in combination with other anticancer medications to treat advanced gastric and colorectal cancers. |
Antilymphocyte immunoglobulin (horse) | A primarily IgG immune globulin used to manage allograft rejection in renal transplant patients. |
Polyestradiol phosphate | Polymeric phosphoric acid ester of estradiol. |
Necitumumab | A monoclonal antibody used to treat metastatic squamous non-small cell lung cancer. |
Ixazomib | A monoclonal antibody used with other medications to treat multiple myeloma in patients who have received one other therapy already. |
Pidotimod | For use as immunostimulant therapy for treatment of cell-mediated immunosuppression with respiratory or urinary infections . |
Roquinimex | Roquinimex is investigated to be used as a treatment of a number of cancers and autoimmune conditions.
As well, roquinimex is researched to be used as adjuvant therapy after bone... |
Masitinib | Masitinib is a tyrosine-kinase inhibitor used in the treatment of mast cell tumors in dogs. It has been available in Europe since 2009, under the brand name Masivet. In the... |
Pirarubicin | Not Annotated |
Aclarubicin | Not Annotated |
Zorubicin | Zorubicin is a drug of the anthracycline class - a class of medications that have historically demonstrated effective chemotherapy for a variety of cancer types. |
Tasonermin | A tumor necrosis factor alpha used along with surgery to remove soft tissue sarcomas of the limbs. |
Temoporfin | A photosensitizer used to treat squamous cell carcinomas of the head and neck. |
Vinflunine | A vinca alkaloid used to treat advanced or metastatic transitional cell carcinoma of the urothelial tract after a platinum containing treatment has failed. |
Treosulfan | Treosulfan is under investigation in Allogeneic Haematopoietic Stem Cell Transplantation. Treosulfan has been investigated for the treatment of Lymphoblastic Leukemia, Acute, Childhood. |
Brodalumab | A monoclonal antibody used to treat moderate to severe plaque psoriasis. |
Tivozanib | Tivozanib has been used in trials studying the treatment and basic science of Solid Tumors, Glioblastoma, Ovarian Cancer, Prostate Cancer, and Stage IV Disease, among others. |
Thymopentin | Thymopentin has been used in trials studying the treatment and prevention of HIV Infections and Hepatocellular Carcinoma. |
Molgramostim | Molgramostim has been used in trials studying the treatment of Bronchiectasis, Cystic Fibrosis, Pulmonary Alveolar Proteinosis, Acute Respiratory Distress Syndrome, and Autoimmune Pulmonary Alveolar Proteinosis. |
Gusperimus | Gusperimus has been used in trials studying the treatment of Lupus Nephritis, Wegeners Granulomatosis, and Wegener's Granulomatosis. |
Balugrastim | Balugrastim has been used in trials studying the treatment of Solid Tumors. |
BCG vaccine | BCG vaccine has been investigated for the treatment of Neoplasms, Bladder Cancer, Neoplasms by Site, Urologic Diseases, and Urologic Neoplasms, among others. |
Cepeginterferon alfa-2B | Cepeginterferon alfa-2B is under investigation in clinical trial NCT01889433 (An Open-label Comparative Efficacy and Safety Study of Algeron (Cepeginterferon Alfa-2b) in Treatment-naive Patients With Chronic Hepatitis C). |
Prednimustine | Prednimustine has been used in trials studying the treatment of Lymphoma. |
Trofosfamide | Trofosfamide has been used in trials studying the treatment of Ependymomas, Medulloblastomas, Sarcoma, Soft Tissue, Supratentorial PNETs, and Recurrent Brain Tumors. |
Mitoguazone | Mitoguazone has been used in trials studying the treatment of Lymphoma, HIV Infections, and Lymphoma, Non-Hodgkin. |
Nimustine | Nimustine has been used in trials studying the treatment of Glioblastoma. |
Lenograstim | The drug is used to reduce the risk of life-threatening infection in patients with neutropenia, particularly after cytotoxic chemotherapy.
Lenograstim is indicated as a treatment to reduce the duration of... |
Lipegfilgrastim | A medication used to reduce the duration of chemotherapy-induced neutropenia and incidence of febrile neutropenia in cytotoxic chemotherapy. |
Gestonorone | Gestonorone is often mistaken for gestonorone capproate which has a different chemical structure. |
Begelomab | Not Annotated |
Tiazofurine | Tiazofurine has potential clinical use in cancer treatment as it is a potential inhibitor of Inosine- 5’-monophosphate (IMP) dehydrogenase . |
Triaziquone | Not Annotated |
Demecolcine | Not Annotated |
Mannosulfan | Not Annotated |
Etoglucid | Not Annotated |
Edrecolomab | Not Annotated |
Lentinan | Not Annotated |
Mitobronitol | Not Annotated |
Mifamurtide | A muramyl dipeptide derivative used to treat high grade, resectable, non-metastatic osteosarcoma after surgical resection. |
Semustine | Not Annotated |
Cridanimod | Not Annotated |
Carboquone | Not Annotated |
Vorozole | Not Annotated |
Paclitaxel poliglumex | Not Annotated |
Oblimersen | Not Annotated |
Ranimustine | Not Annotated |
Megestrol acetate | A progestin that is administered orally to treat anorexia and cachexia or serious unexplained weight loss and is also used as an antineoplastic agent to treat certain types of malignancy. |
Trifluridine | A nucleoside metabolic inhibitor used to treat keratoconjunctivitis and epithelial keratitis caused by simplex virus, and as a part of chemotherapy for certain types of metastatic gastrointestinal cancers. |
Celecoxib | An NSAID used to treat osteoarthritis, rheumatoid arthritis, acute pain, menstrual symptoms, and to reduce polyps is familial adenomatous polyposis. |
Tretinoin | A vitamin A derivative used to treat acne vulgaris, certain types of promyelocytic leukemia, and fine wrinkles. |
Ethinylestradiol | An estradiol used as a contraceptive. |
Histamine | An ingredient of topical drugs for the relief of joint pain or muscle aches and pains. |
Aflibercept | A vascular endothelial growth factor (VEGF) inhibitor used to treat Neovascular (Wet) Age-Related Macular Degeneration (AMD), various types of macular edema and diabetic retinopathy. |
Medroxyprogesterone acetate | A progestin used as a contraceptive and in the treatment of secondary amenorrhea, abnormal uterine bleeding, pain from endometriosis, endometrial and renal carcinomas, paraphilia in males, and GnRH-dependent precocious puberty. |
Floxuridine | An antimetabolite used as palliative management for liver metastases of gastrointestinal malignancy. |
Uracil mustard | Used for its antineoplastic properties. |
Plitidepsin | Intended for the treatment of various forms of cancer. |
Cobimetinib | An antineoplastic agent and selective inhibitor of the mitogen-activated extracellular kinase (MEK) pathway used to treat unresectable or metastatic melanoma. |
Inotuzumab ozogamicin | An antibody-drug conjugate used to treat B-cell precursor acute lymphoblastic leukemia (ALL). |
Olaratumab | A platelet-derived growth factor receptor alpha blocking antibody used with doxorubicin to treat patients with certain types of soft tissue sarcoma (STS). |
Elotuzumab | An antineoplastic agent and SLAMF7-directed immunostimulatory antibody used for the treatment of refractory multiple myeloma in combination with other antineoplastic agents. |
Midostaurin | An antineoplastic agent used to treat high-risk acute myeloid leukemia (AML) with specific mutations, aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematologic neoplasm (SM-AHN), or mast cell leukemia (MCL). |
Dimethyl fumarate | A medication used to treat patients with the relapsing-remitting form of multiple sclerosis. |
Osimertinib | A tyrosine kinase inhibitor used in the treatment of certain types of non-small cell lung carcinoma. |
Daratumumab | A CD38-directed cytolytic antibody used alone or as an adjunct drug in the treatment of multiple myeloma. |
Alectinib | A kinase inhibitor used to treat anaplastic lymphoma kinase positive metastatic non small cell lung cancer. |
Ixekizumab | A monoclonal antibody used to treat moderate to severe plaque psoriasis. |
Venetoclax | A BCL-2 inhibitor used to treat chronic lymphocytic leukemia, small lymphocytic lymphoma, or acute myeloid leukemia. |
Atezolizumab | A monoclonal antibody used to treat advanced or metastatic urothelial carcinoma with disease progression during or up to 12 months after platinum-containing chemotherapy. |
Durvalumab | An antineoplastic monoclonal antibody used to treat urothelial carcinoma and locally advanced, unresectable non-small cell lung cancer. |
Epacadostat | Epacadostat has been used in trials studying the treatment of HL, Melanoma, Glioblastoma, Mucosal Melanoma, and Ovarian Carcinoma, among others. |
Encorafenib | A kinase inhibitor used to treat unresectable or metastatic melanoma with specific mutations. |
Ribociclib | A kinase inhibitor used to treat HR+, HER2- advanced or metastatic breast cancer. |
Icotinib | Icotinib hydrochloride is a novel epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor, exhibits encouraging efficacy and tolerability in patients with advanced non-small-cell lung cancer (NSCLC) who failed previous chemotherapy. |
Talazoparib | A poly-ADP ribose polymerase inhibitor used to treat HER2-, BRCA mutated locally advanced or metastatic breast cancer. |
Sarilumab | A monoclonal antibody used to treat moderate to severe rheumatoid arthritis who have responded poorly or are intolerant of other DMARDs. |
Niraparib | A poly-ADP ribose polymerase inhibitor used to treat recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer responding to platinum based chemotherapy. |
Sirukumab | Sirukumab has been used in trials studying the treatment and basic science of Giant Cell Arteritis and Arthritis, Rheumatoid. |
Baricitinib | A Janus kinase inhibitor used to treat moderate to severe rheumatoid arthritis that has responded poorly to at least one TNF antagonist. |
Neratinib | A protein kinase inhibitor used to treat breast cancer that over expresses the HER2 receptor. |
Guselkumab | A monoclonal antibody used to treat moderate to severe plaque psoriasis. |
Apalutamide | An androgen receptor inhibitor used to treat non metastatic, castration resistant prostate cancer. |
Rociletinib | Rociletinib has been used in trials studying the treatment and prevention of Nonsmall Cell Lung Cancer, Non-small Cell Lung Cancer, and Locally Advanced or Metastatic Non-small Cell Lung Cancer. |
Avelumab | A monoclonal antibody used to treat metastatic merkel cell carcinoma, metastatic urothelial carcinoma, or renal cell carcinoma. |
Dacomitinib | A medication used to treat non small cell lung cancer with EGFR exon 19 deletion of exon 21 L858R substitution. |
Binimetinib | A medication used to treat metastatic melanoma with specific mutations. |
Ocrelizumab | A CD20 specific monoclonal antibody used to treat relapsing remitting multiple sclerosis. |
Vosaroxin | Vosaroxin is under investigation for the treatment of Leukemia, Myeloid, Acute. |
Abemaciclib | A medication used to treat HR+ HER2- advanced or metastatic breast cancer. |
Lorlatinib | An anaplastic lymphoma kinase inhibitor used to treat anaplastic lymphoma kinase positive metastatic non small cell lung cancer. |
Brigatinib | An anaplastic lymphoma kinase inhibitor used to treat anaplastic lymphoma kinase positive metastatic non small cell lung cancer. |
Rucaparib | An anti-cancer agent used to treat recurrent ovarian, fallopian tube, or peritoneal cancer. |
Copanlisib | A medication used to treat relapsed follicular lymphoma who have attempted at least two other treatments. |
Mogamulizumab | A monoclonal antibody used to treat relapsed or refractory mycosis fungoides or Sézary syndrome after attempting one other therapy. |
Ozanimod | A sphingosine 1-phosphate receptor modulator being studied to treat Multiple Sclerosis (MS) and inflammatory bowel disease (IBD). |
Olmutinib | For use in treatment of metastatic T790M mutation positive non-small cell lung cancer . |
Enasidenib | An isocitrate dehydrogenase-2 inhibitor used to treat relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 mutation. |
Talimogene laherparepvec | A genetically modified virus used to treat recurrent melanoma, or metastatic melanoma. |
Tildrakizumab | An interleukin-23 antagonist used to treat moderate to severe plaque psoriasis. |
Emapalumab | An interferon gamma blocking antibody used to treat primary hemophagocytic lymphohistiocytosis. |
Pegademase | A modified form of bovine adenosine deaminase used to treat adenosine deaminase deficiency, a condition which leads to the formation of adenosine metabolites which are cytotoxic to lymphocytes. |
Bermekimab | Bermekimab is under investigation in clinical trial NCT01384630 (Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis). |
Etirinotecan pegol | Etirinotecan pegol is under investigation in clinical trial NCT01663012 (Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma). |
Ropeginterferon alfa-2b | Ropeginterferon alfa-2b is under investigation in clinical trial NCT01949805 (Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera). |
Pegteograstim | Pegteograstim is under investigation in clinical trial NCT02787876 (Pegteograstim in Children With Solid Tumors). |
Padeliporfin | Not Annotated |
Interferon Gamma | Interferon gamma is a Type 1 inflammatory cytokine and the only type II interferon. It has antitumor properties, antiviral activities, and important immunoregulatory functions. The interferon is primarily produced by... |
Ravulizumab | A monoclonal antibody used to treat paroxysmal nocturnal hemoglobinuria. |
Acalabrutinib | A Bruton tyrosine kinase inhibitor used to treat mantle cell lymphoma, chronic lymphocytic leukemia, and small lymphocytic lymphoma. |
Entinostat | Entinostat is under investigation for the treatment and other of Volunteers, Breast Cancer, Human Volunteers, and Normal Volunteers. Entinostat has been investigated for the treatment of Non-Small Lung Cancer, Epigenetic... |
Selinexor | Selinexor is indicated for the treatment of relapsed or refractory multiple myeloma in combination with dexamethasone.[label] Patients must have received at least 4 prior therapies and have disease which is... |
Glasdegib | A sonic hedgehog receptor inhibitor used to treat newly diagnosed acute myeloid leukemia in patients over 75 years who cannot receive intense chemotherapy. |
Entrectinib | Entrectinib is indicated for the treatment of metastatic ROS1-positive non-small cell lung cancer in adults. Entrectinib is also indicated in adults and children over 12 years old for the treatment... |
Alpelisib | Alpelisib is indicated in combination with fulvestrant to treat postmenopausal women, and men, with advanced or metastatic breast cancer.[Label] This cancer must be hormone receptor (HR)-positive, human epidermal growth factor... |
Gilteritinib | An AXL receptor tyrosine kinase inhibitor used to treat relapsed or refractory acute myeloid leukemia. |
Siponimod | A medication used to treat relapsing multiple sclerosis. |
Belotecan | Belotecan has been investigated for the treatment of Epithelial Ovarian Cancer. |
Fedratinib | Fedratinib is indicated to treat adults with primary or secondary myelofibrosis that is either intermediate-2 or high risk. |
Quizartinib | Quizartinib is under investigation in Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies. It is a potent inhibitor of FLT3. |
Darolutamide | An androgen receptor antagonist used for castration-resistant, non-metastatic prostate cancer. |
Ivosidenib | An isocitrate dehydrogenase-1 inhibitor used to treat acute myeloid leukemia with a susceptible mutation. |
Cemiplimab | A programmed death receptor-1 blocking antibody used to treat metastatic cutaneous squamous cell carcinoma. |
Elapegademase | A recombinant adenosine deaminase used to treat adenosine deaminase severe combined immune deficiency. |
Larotrectinib | A kinase inhibitor used to treat solid tumors with neurotrophic receptor tyrosine kinase gene fusion, are metastatic, high risk for surgery, or have no alternative treatments. |
Tagraxofusp | A CD123-directed cytotoxin used to treat plasmacytoid dendritic cell neoplasm. |
Risankizumab | An interleukin-23 antagonist used to treat moderate to severe plaque psoriasis. |
Upadacitinib | An oral Janus kinase (JAK)1-selective inhibitor used in the treatment of moderate to severe rheumatoid arthritis in adult patients who did not respond well to methotrexate. |
Imlifidase | A cysteine protease that specifically cleaves human IgG antibodies, facilitating kidney transplantation in HLA sensitized patients. |
Empegfilgrastim | Empegfilgrastim is under investigation in clinical trial NCT01569087 (Dose-finding Study of Empegfilgrastim for Neutropenia Prophylaxis in Patients With Breast Cancer). |
Darvadstrocel | Darvadstrocel is a type of adipose-derived mesenchymal stem cell (http://https://go.drugbank.com/drugs/DB15729). |